Within-trial cost and 1year cost-effectiveness of the DiRECT/Counterweight-Plus weightmanagement programme to achieve remission of type 2 diabetes. Lancet
Main text
Word count: 1,131 (original draft: 976) Type 2 diabetes affects 8% of adults worldwide, 1 leading to 15% excess mortality 2 and 67% excess disabilities. 3 In 2017, people with diabetes accounted for 24% of all US healthcare spending: diabetes-attributable costs were $327 billion, comprising $237 billion in direct healthcare costs, equivalent to $9601 per person, plus $90 bn in losses of productivity. Costs rise with age, steeply above 45 years, reflecting the large contribution from type 2 diabetes. 4 In the UK, diabetes accounts for approximately 10% of total National Health Service (NHS) budget, 5 with direct costs of £2564 per patient per year at 2010-11 prices (accounting for inflation, £2801 per year in 2016-17). 6 Type 2 diabetes is being diagnosed at younger ages, with more complications, as populations become more overweight, and costs are rising rapidly with increasing prevalence and new, more expensive treatments. Management focuses heavily on pharmacotherapy, but morbidity and mortality remain high. 7 Bariatric surgery, with its own complications, can induce remission of type 2 diabetes but reaches only 1% of the eligible population, so periods of remission through primary care-based interventions could be valuable. In the DiRECT trial (ISRCTN03267836), 68 (46%) of 149 participants assigned to the study intervention achieved remission of type 2 diabetes after intensive weight management in routine primary care compared with six (4%) of 149 participants assigned to usual-care. [7] [8] [9] We did a cost-effectiveness analysis of the Counterweight-Plus intervention used in DIRECT, with cost per additional diabetes remission at 1 year calculated from an intention to treat analysis of DIRECT and the differences in costs (UK NHS perspective, 2017 prices) and effects between the Counterweight-Plus and usual-care groups (appendix).
The DiRECT/Counterweight-Plus intervention involves fixed 'set-up' costs, for Counterweight specialists to train practitioners (practice nurses or dietitians who see participants), practitioners' attendance time, dedicated training materials, and programme support including online access to a medical advisor under an annual licence fee. Resource use (table) was collected prospectively throughout the study for every participant, including formula diet sachets (as total diet replacement [soups and shakes, 825-853 kcal per day for 12-20 weeks] then reducing over stepped food reintroduction, plus optional daily meal-replacement sachets during weight loss maintenance, and for rescue packages), review appointments with a practitioner, and supporting workbooks costed in full for all randomly assigned intervention participants. 7 Total cost per intervention participant of delivering the DiRECT/Counterweight-Plus programme was £1223 (95%CI £1147-£1294); the largest cost components were practitioner visits (£447 per participant; 37% of total intervention cost) and formula diet sachets (495 sachets [£708] per participant; 58% of total intervention cost).
Data for routine health-care contacts and medication use were collected directly from general practitioner (GP) records for both groups. Antidiabetes and antihypertensive medications, suspended on commencing the intervention and reinstated as necessary under clinical guidelines, were costed from observed individual participants' treatments. The intervention group had significantly lower cost per participant than did controls for antidiabetes drugs (mean difference £120, 95%CI 78-163), antihypertensive drugs (£14, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , diabetes-related GP visits (£17, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , and diabetes-unrelated practice nurse visits (£6, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . No significant differences were observed for other care contacts.
Reduced routine resource use thus provides some cost offset within the first year. Mean 1-
year management cost per participant (intervention delivery plus routine NHS costs) (n=149 in both groups) was £1913 (SD 1161) versus £846 (1066) for controls, thus incremental intervention cost was £1067(820-1322; figure) . The incremental cost per additional 1-year remission (difference in costs, divided by difference in remissions [41·6%]) was £2564(95%CI £1867-£3453).
We have not attempted to project precise costs for the DiRECT / four times greater 1-year remission rate (46% vs.12%). 10, 11 The medication cost savings resulted from discontinuation antidiabetes and antihypertensive drugs on commencing the intervention, and from the lesser likelihood of their reintroduction and effects on subsequent dose or number of drugs used (via a guideline-based protocol) if the participant lost weight. The number of prescribed antidiabetes and antihypertensive medications was more than halved at 12 months in the intervention group. 8 Use of other concomitant medications was similar across groups over the first 12 months. 8 Coupled with the low costs of most other medications, an aggregated difference between study groups seems unlikely; detailed evaluation of concomitant medications was therefore excluded from the present 12-month analysis.
DiRECT is the first non-surgical study to set remission of type 2 diabetes as a primary outcome and is implemented entirely within primary care. The relative costs of the intervention, and of routine diabetes care, are similar in other studies. DiRECT participants were very typical of people currently living with type 2 diabetes within 6 years of diagnosis. A high proportion were from socially deprived circumstances, where type 2 diabetes is most prevalent and difficult to manage. 10 Our results are thus likely to be robust and widely transferable. However, the population studied was almost entirely of white European ethnic origin; evidence is needed for people from other racial or ethnic backgrounds in whom type 2 diabetes has different characteristics.
Our immediate objective here is to report the costs of mounting an intervention with evident clinical benefits over the short term, potentially for a large proportion of people with type 2 diabetes, whose current management is expensive and growing. The offsetting cost savings seen in the first 12 months of the trial were modest, but reduced healthcare demand might persist into future years after the initial intervention costs are completed. Remission is an incentivising target for diabetes care but 14% (5/36) did not achieve remission despite substantial weight loss. 9 However, weight loss has many other personal, clinical and public health benefits. Studies using different methods suggest reduced life expectancy with type 2 diabetes of 6-7 years in younger people, 6, 12 and substantial weight loss consistently improves multiple cardiometabolic risk factors, potentially extending life expectancy. 13, 14 Our analysis suggests that each case of remission costs £2564 on average, as a basis for budget planning and providing a platform for long-term cost-effectiveness. On-going follow-up of DiRECT will inform modelling of long-term health gains, resource savings, and quality of life. Participants' abilities to maintain weight loss and to avoid relapse of diabetes will be critical to enhance long-term cost-effectiveness, requiring appropriate research and development investment for programme improvement. However, based on this within-trial analysis, irrespective of any marginal efficiencies from delivering the weight-management programme in routine practice and the exact cost per quality-adjusted life-year gained, the case already seems strong for diabetes care budgets to offer the support for patients to attempt remission.
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The Diabetes Remission Clinical Trial (DiRECT) assesses the extent to which effective weight management, delivered in the primary care setting, can lead to sustained remission of type 2 diabetes. 1, 2 DiRECT is an open-label, cluster-randomised trial at 49 primary care practices in Scotland and the Tyneside region of England. 12-month follow-up is completed, extended follow-up is ongoing. The geographical regions included in DiRECT represent the patient characteristics and poorer social settings where type 2 diabetes is most frequent. Eligibility criteria included age 20-65 years, type 2 diabetes diagnosed within the previous 6 years, BMI of 27-45 kg/m 2 , and most recent HbA1c greater than 48 mmol/mol (6·5%) (or >43 mmol/mol [6%] if taking diabetes medication). Between July, 2014, and August, 2016, 298 participants were randomly assigned equally to control (usual care) and intervention groups. Both groups continued to receive optimal routine care under current clinical guidelines.
Participants in the intervention group followed the Counterweight-Plus weight-management programme, which aims to achieve and maintain substantial weight loss, aiming for >15 kg loss. The programme, delivered in the primary care setting by trained dietitians or practice nurses, contains three phases: total diet replacement (TDR), when participants consume only a low-energy formula diet (soups and shakes that contained 825-853 kcal/day; 59% carbohydrate, 13% fat, 26%, protein, 2% fibre) for 12 weeks, followed by a structured food reintroduction (FR) (approximately 50% carbohydrate, 35% total fat, and 15% protein) phase of 2-8 weeks, and then longer-term weight loss maintenance (WM). The programme allows some flexibility within defined ranges for duration of phases and maintenance diet composition, with support at regular review appointments with a dietitian or practice nurse (more frequently during the TDR and FR phases). Following weight loss, rescue packages of the formula diet may be provided if >2 kg weight is regained or diabetes returns. All oral antidiabetes and antihypertensive medications are ceased, on safety grounds, when participants begin the programme. These are reintroduced according to standard protocols under national clinical guidelines, where indicated by regular monitoring of blood glucose and blood pressure. Otherwise, participants in both groups continued to receive diabetes care under current National Health Service guidelines and standards. 3, 4 Further details of the DIRECT study design and intervention and 1-year clinical results have been published previously. 1, 2, 5, 6 
